Chad J Achenbach Selected Research

Chad J Achenbach Research Topics

Disease

17	COVID-19 04/2024 - 12/2020
14	Neoplasms (Cancer) 11/2023 - 03/2011
13	Infections 04/2024 - 02/2011
5	Acquired Immunodeficiency Syndrome (AIDS) 01/2022 - 03/2011
4	Tuberculosis (Tuberculoses) 01/2020 - 06/2013
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2019 - 06/2014
4	Lymphoma (Lymphomas) 01/2017 - 08/2013
3	HIV Infections (HIV Infection) 01/2020 - 02/2011
3	Kaposi Sarcoma (Kaposi's Sarcoma) 01/2017 - 10/2015
3	Viremia 01/2016 - 01/2014
2	Breakthrough Infections 07/2022 - 09/2021
2	Anus Neoplasms (Anal Cancer) 01/2022 - 01/2020
2	Coinfection 01/2022 - 01/2022
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2018 - 01/2016
2	Immune Reconstitution Inflammatory Syndrome 07/2014 - 02/2012
1	COVID-19 related adult multisystem inflammatory disease 11/2023
1	Pneumonia (Pneumonitis) 03/2022
1	Respiratory Tract Infections (Respiratory Tract Infection) 03/2022
1	Human Influenza (Influenza) 03/2022
1	Alcoholism (Alcohol Abuse) 01/2022
1	Hypertension (High Blood Pressure) 01/2021
1	Hepatitis 01/2021
1	Hepatocellular Carcinoma (Hepatoma) 01/2021
1	Coronary Artery Disease (Coronary Atherosclerosis) 06/2018
1	Pathologic Constriction (Stenosis) 06/2018
1	Carcinogenesis 01/2018
1	Heart Failure 11/2017
1	Myocardial Infarction 01/2017
1	Lung Neoplasms (Lung Cancer) 10/2015
1	Cardiovascular Diseases (Cardiovascular Disease) 06/2015
1	Pulmonary Tuberculosis 05/2015
1	Obstructive Lung Diseases (Obstructive Lung Disease) 05/2015
1	Chronic Obstructive Pulmonary Disease (COPD) 05/2015
1	Hepatitis B 07/2014
1	Persistent Infection 01/2014
1	Opportunistic Infections (Opportunistic Infection) 02/2012
1	Hyperlipidemias (Hyperlipidemia) 02/2011
1	Insulin Resistance 02/2011

Drug/Important Bio-Agent (IBA)

14	RNA (Ribonucleic Acid)IBA 09/2023 - 03/2011
5	Biomarkers (Surrogate Marker)IBA 11/2023 - 01/2018
5	Explosive Agents (Explosives)IBA 01/2021 - 12/2020
4	COVID-19 VaccinesIBA 04/2024 - 09/2021
4	AntigensIBA 01/2023 - 01/2022
3	Viral RNAIBA 09/2023 - 01/2017
3	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 03/2015
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 02/2023 - 06/2015
2	AntibodiesIBA 01/2023 - 01/2014
2	Coffee FDA Link 03/2022 - 06/2021
2	Antiviral Agents (Antivirals)IBA 01/2022 - 06/2015
2	VaccinesIBA 01/2021 - 01/2021
1	C-Reactive ProteinIBA 11/2023
1	fibrin fragment D (D-dimer)IBA 11/2023
1	ProcalcitoninIBA 11/2023
1	Ferritins (Ferritin)IBA 11/2023
1	Proteins (Proteins, Gene)FDA Link 01/2023
1	Nucleocapsid ProteinsIBA 01/2023
1	EpitopesIBA 01/2023
1	Peptides (Polypeptides)IBA 01/2023
1	TeaIBA 03/2022
1	Caffeine (No Doz)FDA LinkGeneric 03/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	Indicators and Reagents (Reagents)IBA 01/2022
1	Complement System Proteins (Complement)IBA 08/2021
1	Hepatitis B e AntigensIBA 01/2021
1	Antihypertensive Agents (Antihypertensives)IBA 01/2021
1	Surface Antigens (Surface Antigen)IBA 01/2021
1	Sodium Dodecyl Sulfate (Sodium Lauryl Sulfate)IBA 11/2019
1	Rifampin (Rifampicin)FDA LinkGeneric 12/2018
1	MicroRNAs (MicroRNA)IBA 01/2018
1	Papillomavirus Vaccines (HPV Vaccines)IBA 01/2018
1	SmokeIBA 05/2015
1	GoldIBA 05/2015
1	Bronchodilator Agents (Bronchodilators)IBA 05/2015
1	N-acetoacetyl-N-deacetylcolchicineIBA 04/2014
1	Broadly Neutralizing AntibodiesIBA 01/2014
1	BilirubinIBA 02/2011
1	Protease Inhibitors (Protease Inhibitor)IBA 02/2011
1	Atazanavir Sulfate (Reyataz)FDA Link 02/2011
1	Ritonavir (Norvir)FDA Link 02/2011

Therapy/Procedure

17	Therapeutics 01/2022 - 03/2011
11	Art Therapy 01/2022 - 02/2012
6	Highly Active Antiretroviral Therapy (HAART) 01/2021 - 02/2011
1	Percutaneous Coronary Intervention 06/2018
1	Aftercare (After-Treatment) 01/2018
1	Drug Therapy (Chemotherapy) 01/2017
1	Hysterectomy 01/2016